Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
106.93
(
0.00%
)
Bitcoin
70,965.01
(
0.64%
)
News Focus
News Focus
Post# of 257267
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 209574

Tuesday, 03/07/2017 1:05:42 PM

Tuesday, March 07, 2017 1:05:42 PM

Post# of 257267
More on BCPIA Patent Dance:

https://www.pharmapatentsblog.com/2017/03/07/court-dismisses-avastin-biosimilar-complaint

Roche/Genentech now argues that AMGN cannot partially opt out of the BCPIA Patent Dance, and that once AMGN voluntarily handed its 351(k) application to Roche for inspection (as dictated by the Patent Dance) it forfeited its right to discontinue the remainder of the Patent Dance procedures.

AMGN disagrees, and asserts that Roche’s only legal remedy is to sue AMGN for patent infringement.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today